Key Takeaways Amgen is advancing MariTide, a monthly obesity drug, in multiple phase III studies under its MARITIME program. MariTide showed up to 20% weight loss in obese non-diabetic patients, but lagged expectations. Amgen stock is up 8.9% YTD and trades below industry valuation, with rising 2025 and 2026 earnings estimates.Amgen (AMGN) is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the booming weight loss drug market. The obesity market is ...